- Author
- Lien Van Hoecke (UGent) , Rein Verbeke (UGent) , Heleen Dewitte (UGent) , Ine Lentacker (UGent) , Karim Vermaelen (UGent) , Karine Breckpot and Sandra Van Lint (UGent)
- Organization
- Abstract
- mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its many advantages have paved the path beyond this application. In addition, due to smart design of both the structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability and selective targeting, the therapeutic potential of mRNA can be considered as endless.As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a rationale for their clinical application.
- Keywords
- Molecular Medicine, Cancer Research, Oncology, Cancer, mRNA, Nanoparticle, Antibody, Dendritic cell, T cell, Cytokine, Tumor microenvironment
Downloads
-
Published review.pdf
- full text (Published version)
- |
- open access
- |
- |
- 1.64 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8710728
- MLA
- Van Hoecke, Lien, et al. “MRNA in Cancer Immunotherapy : Beyond a Source of Antigen.” MOLECULAR CANCER, vol. 20, no. 1, 2021, doi:10.1186/s12943-021-01329-3.
- APA
- Van Hoecke, L., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K., Breckpot, K., & Van Lint, S. (2021). mRNA in cancer immunotherapy : beyond a source of antigen. MOLECULAR CANCER, 20(1). https://doi.org/10.1186/s12943-021-01329-3
- Chicago author-date
- Van Hoecke, Lien, Rein Verbeke, Heleen Dewitte, Ine Lentacker, Karim Vermaelen, Karine Breckpot, and Sandra Van Lint. 2021. “MRNA in Cancer Immunotherapy : Beyond a Source of Antigen.” MOLECULAR CANCER 20 (1). https://doi.org/10.1186/s12943-021-01329-3.
- Chicago author-date (all authors)
- Van Hoecke, Lien, Rein Verbeke, Heleen Dewitte, Ine Lentacker, Karim Vermaelen, Karine Breckpot, and Sandra Van Lint. 2021. “MRNA in Cancer Immunotherapy : Beyond a Source of Antigen.” MOLECULAR CANCER 20 (1). doi:10.1186/s12943-021-01329-3.
- Vancouver
- 1.Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, et al. mRNA in cancer immunotherapy : beyond a source of antigen. MOLECULAR CANCER. 2021;20(1).
- IEEE
- [1]L. Van Hoecke et al., “mRNA in cancer immunotherapy : beyond a source of antigen,” MOLECULAR CANCER, vol. 20, no. 1, 2021.
@article{8710728,
abstract = {{mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its many advantages have paved the path beyond this application. In addition, due to smart design of both the structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability and selective targeting, the therapeutic potential of mRNA can be considered as endless.As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a rationale for their clinical application.}},
articleno = {{48}},
author = {{Van Hoecke, Lien and Verbeke, Rein and Dewitte, Heleen and Lentacker, Ine and Vermaelen, Karim and Breckpot, Karine and Van Lint, Sandra}},
issn = {{1476-4598}},
journal = {{MOLECULAR CANCER}},
keywords = {{Molecular Medicine,Cancer Research,Oncology,Cancer,mRNA,Nanoparticle,Antibody,Dendritic cell,T cell,Cytokine,Tumor microenvironment}},
language = {{eng}},
number = {{1}},
pages = {{14}},
title = {{mRNA in cancer immunotherapy : beyond a source of antigen}},
url = {{http://doi.org/10.1186/s12943-021-01329-3}},
volume = {{20}},
year = {{2021}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: